MétaCan
Menu
Back to cohort

First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).

2014· article· en· W2600545212 on OpenAlexaff
Elizabeth A. Griffiths, Hagop M. Kantarjian, Gail J. Roboz, Patricia Kropf, Casey L. O’Connell, Karen Yee, Guillermo Garcia‐Manero, Elias Jabbour, Eric J. Feldman, Katherine Walsh, David A. Rizzieri, Wendy Stock, Scott D. Lunin, Sue Naim, Gavin Choy, Pietro Taverna, Yong Hao, Mohammad Azab, Woonbok Chung, Jean‐Pierre J. Issa

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineRegimenClinical endpointInternal medicineNeutropeniaRefractory (planetary science)Phases of clinical researchGastroenterologySurgeryDecitabineClinical trialChemotherapy

Abstract

fetched live from OpenAlex

7030 Background: SGI-110 is a novel HMA administered as a small volume injection which results in extended decitabine exposure. We previously reported an Overall Complete Remission (OCR=CR+CRi+CRp) rate of 16% in 50 patients with r/r AML using SGI-110 daily x 5 regimen with either 60 or 90 mg/m2/d (Kantarjian et al, 2013). We report here the first results of the daily x 10 Q 28 days regimen using 60 mg/m2/d. Methods: Patients with AML who relapsed or progressed following prior treatment were enrolled. There was no limit on the number of prior treatment regimens, total WBC, or blast %. The primary endpoint was OCR using modified IWG 2003 criteria. Secondary efficacy endpoints included duration of response, and Overall Survival. Safety was assessed using the CTCAE Version 4. After 2-4 cycles, investigators were allowed to consolidate with daily x 5 at 60 mg/m2/d regimen until progression. Results: The study completed enrolment with 53 patients treated. Patients had a median age of 57 years (range 29-82), 51% were male, 83% had ECOG PS of 0-1, and 17% had ECOG PS 2. Median number of prior regimens was 2 (range 1-7); 13% of patients had prior HMA treatment. The primary efficacy endpoint of OCR was reported in 16 patients (7 CR, 6 CRi, and 3 CRp) or an OCR rate of 30% (95% CI: 18.3%, 44.3%). Seven patients are still on treatment. 30-day and 60-day mortality were 1.9% and 11.3% respectively. Of 162 total number of cycles given at the data cutoff, 149 (92%) were given using the 10-day regimen and 13 (8%) were given using the daily x 5 consolidation. The most common drug-related Grade ≥3 AEs were: anaemia and thrombocytopenia (19% each), neutropenia and febrile neutropenia (5.7% each). Conclusions: SGI-110 given as a daily x 10 SC regimen at a dose of 60 mg/m2/d was clinically active in heavily pretreated population of r/r AML with an acceptable safety profile. The results appear to compare favorably with our previously reported complete remission response rate in a similar patient population using the daily x 5 regimen at doses of 60 or 90 mg/m2/d. These results warrant further investigation of this regimen for the treatment of r/r AML. Clinical trial information: NCT01261312.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.154
GPT teacher head0.464
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicAcute Myeloid Leukemia ResearchFrench-language works237,207